SELB -33% on (more) phase-2 gout data: https://globenewswire.com/news-release/2018/10/23/1625289/0/en/Selecta-Biosciences-Presents-New-Interim-Data-from-Phase-2-Trial-of-SEL-212-in-Development-for-Chronic-Severe-Gout-at-ACR-2018.html